Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Oppenheimer Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $53

Author: Benzinga Newsdesk | August 07, 2024 07:51am
Oppenheimer analyst Matthew Biegler maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $60 to $53.

Posted In: IDYA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist